Evaluating PT027 vs. PT007 for Asthma
Phase 3
440
about 3.4 years
12–17
94 sites in AK, AR, AZ +33
About this study
This trial is testing whether a new treatment, PT027, is better than PT007 at preventing severe asthma attacks in children and teens with asthma who have had a severe attack recently. Participants will use the treatments as needed when they feel symptoms of asthma.
Based on ClinicalTrials.gov records.
What participants do
- 1.Use AS MDI
- 2.Use BDA MDI
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
inhaled
Secondary: Apparent total body clearance (CL/F), Maximum Observed Concentration (Cmax), Number of participants with adverse events (AEs) and severe adverse events (SAEs), Terminal elimination half-life (t½λz), Time to first (TTF) severe asthma exacerbation, Time to reach maximum concentration following drug administration (Tmax)
Respiratory